Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron, the active ingredient in Ondansetron Kabi, is a 5‑HT3 receptor antagonist presented as a tablet for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative settings in adults and children.

GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is a 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting across several clinical pathways.

Chemotherapy‑induced nausea and vomiting: reduces incidence and severity of acute and delayed episodes. Radiation‑induced nausea and vomiting: provides effective control during and after radiotherapy. Postoperative nausea and vomiting: prevents early and late postoperative episodes, improving patient comfort.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Diarrhoea - Abdominal discomfort

Serious or Rare Side Effects: - QT interval prolongation leading to cardiac arrhythmia - Severe allergic reactions such as anaphylaxis - Serotonin syndrome when combined with serotonergic agents - Cardiac arrest in susceptible individuals - Severe hypotension

Precautions should be observed before initiating therapy with Ondansetron. - Cardiac assessment: evaluate baseline QT interval and correct electrolyte imbalances. - Concomitant medications: avoid or monitor drugs that also prolong QT interval. - Hepatic impairment: consider dose adjustment in patients with severe liver dysfunction. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Electrolyte monitoring: correct hypokalaemia or hypomagnesaemia before treatment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Apomorphine: co‑administration can cause severe hypotension and loss of consciousness. - Other QT‑prolonging agents (e.g., quinidine, amiodarone): increase risk of cardiac arrhythmias. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): reduce ondansetron plasma levels, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Atypical antipsychotics (e.g., olanzapine): may enhance QT prolongation; monitor ECG. - Dexamethasone and other corticosteroids: may require dose adjustment of ondansetron for optimal antiemetic effect.